Signaling by transforming growth factor (TGF)-β, a regulator of several biological processes including renal fibrosis, is mediated, in part, by the Smad proteins. Tight control of Smad level and activity is critical for proper T G F -β biological functions.
the protein and transcriptional level. Smad3 down-regulation could represent a feedback loop controlling TGF-β signaling in a cell phenotype-specific manner.
Glomerulosclerosis and tubulointerstitial fibrosis are the consequences of excessive extracellular matrix (ECM) accumulation and lead to end-stage renal failure (1) . TGF-β is a pleiotropic cytokine that regulates a variety of physiological and pathological processes in a cell type-specific manner and plays a central role in the development of fibrosis. In mesenchymal cells such as fibroblasts, activated hepatic stellate cells and glomerular mesangial cells, TGF-β leads to ECM accumulation (2) (3) (4) . TGF-β contributes to embryogenesis, fibrosis and carcinogenesis in part by stimulating epithelial-to-mesenchymal transition (EMT) (5, 6) . In addition TGF-β inhibits proliferation in non-transformed epithelial, haematopoetic and endothelial cells; and stimulates differentiation of leukocytes and apoptosis of cells such as podocytes, hepatocytes and renal tubular and prostatic epithelial cells (3, 4, (7) (8) (9) .
TGF-β-family receptors transduce signal to the nucleus through the Smads. These proteins are divided into receptor-regulated or R-Smads Smad1, Smad2, Smad3, Smad5 and Smad8; c o m m o n -p a r t n e r or C o -S m a d Smad4; and inhibitory Smads or I-Smads Smad6 and Smad7 (10) (11) (12) (13) . A critical role for Smad3 as a mediator of fibrosis has been established using in vitro and in vivo models examining various tissues and organs (14) . Using TGF-β1-treated human mesangial cells as our model for kidney fibrosis, we have shown that Smad3 is necessary for TGF-β1 -stimulated α2(I) collagen (COL1A2) promoter activity (15, 16) . However, 24 h of TGF-β1 treatment decreases Smad3 levels in these cells (15) .
Recent studies have shown that several members of the Smad protein family can be degraded by the ubiquitin-proteasome pathway (17) . However, only a few reports have examined Smad3 turnover. In addition, these studies were performed mainly with overexpressed proteins, with Smad3 ubiquitination observed in cells transfected with Smad3 and ubiquitin, in the presence of a proteasome inhibitor and/or overexpression of an E3 ubiquitin ligase (18) (19) (20) .
Here, we investigated the regulation of the expression of endogenous Smad3, a central participant in the mechanisms by which TGF-β1 triggers events that contribute to fibrotic diseases. Our results indicate that both increased degradation and decreased promoter activity contribute to the TGF-β1-mediated decrease in Smad3 expression.
EXPERIMENTAL PROCEDURES
Materials. Reagents were purchased from the following vendors: active, human recombinant TGF-β1 from R&D Systems (Minneapolis, MN); rabbit anti-phospho-Smad3 (Ser433/435) and mouse anti-ubiquitin from Cell Signaling (Beverly, MA); mouse anti-Smad4 (B-8), mouse anti-Smad1/2/3 (H-2), rabbit anti-Dab2, antimouse IgG-Horseradish Peroxidase (HRP) and anti-goat IgG-HRP, from Santa Cruz Biotechnology (Santa Cruz, CA); anti-rabbit IgG-HRP, Luciferase and βgalactosidase assay systems from Promega (Madison, WI); rabbit anti-Smad3, rabbit anti-Smad2 and protein G-Sepharose from Invitrogen Zymed Laboratories (Carlsbad, CA); mouse anti-E-cadherin (BD Transduction Laboratories, San Jose, CA); actinomycin D, cycloheximide, proteasome inhibitor I, lactacystin and Z-Leu-Leu-al (MG132) from Sigma (St Louis, MO). The Alk5/TβRI inhibitor SB-431542 (21) was a generous from gift Dr. N. Laping (GlaxoSmithKline Pharmaceuticals, King of Prussia, PA). Stock solutions were made as followed: 4 µg/ml TGF-β 1 in 4 mM HCl containing 1 mg/ml bovine serum albumin; 10 mM proteasome inhibitor I, lactacystin and MG132 in DMSO; 1 mg/ml actinomycin D in DMSO; 1 mg/ml cycloheximide in water.
Cell culture. Human glomerular mesangial cells were isolated and grown in DMEM:F12 with 20% new born calf serum (NBCS), penicillin/streptomycin, Hepes buffer, sodium pyruvate, 8 µg/ml insulin and glutamine. as previously described (15) . The renal tubular epithelial cell line HKC, obtained from Dr. L. Racusen (22) was cultured in DMEM:F12 supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin, Hepes buffer and glutamine.
Animals. Male CD-1 mice that weighed approximately 18 to 20 g were obtained from Harlan Sprague-Dawley (Indianapolis, IN). Unilateral ureteral obstruction (UUO) was performed as described (23) . Sham-operated mice had their ureters exposed and manipulated but not ligated. Mice were killed 3, 7 and 14 days after surgery. Kidneys were snap-frozen in liquid nitrogen and stored at -80°C before protein extractions.
Immunoprecipitation and western blot analysis. Cells were switched to medium containing 1% NBCS (for mesangial cells) or 0.5% FBS (for HKC), and treated with 1 ng/ml T G F -β 1 for various time periods leading to simultaneous harvest. In some experiments, the cells were incubated with inhibitors for 1 h prior to T G F -β 1 treatment. The cells were lysed as described (16) . Kidney tissues were homogenized and proteins were extracted as described (23) . For immunoprecipitation experiments, 500 µg of lysates were immunoprecipitated with 1.25 µg anti-Smad3 antibody and 50 µl protein GSepharose. Immunoprecipitates and whole cell lysates were analyzed by immunoblotting. Densitometric analysis was performed as described (24) .
RNA isolation and Northern blot. Total RNA was harvested using Trizol (Invitrogen) according to the manufacturer's protocol and analyzed by Northern blot with cDNA probes for human Smad3 (25) and bovine 28S ribosomal RNA (provided by Dr. H. Sage, University of Washington, Seattle, WA) as described previously (15) .
Transient transfection and luciferase assay. Transfection was performed with the Fugene6 transfection reagent (Roche Applied Science) and luciferase and β galactosidase activities were measured as previously described (15, 26) . Briefly, 8 to 10 x 10 4 cells were seeded in 6-well plates. Eighteen hours later, cells were switched to 1% NBCS-containing medium and transfected with the Smad3-LUC constructs along with CMV-β galactosidase (Invitrogen) as a control of transfection efficiency. One hour later, 1 ng/ml TGF-β1 or control vehicle was added and the cells were harvested after 18-24 h. Luciferase assay results were normalized for β galactosidase activity. Experimental points were performed in triplicates in several independent experiments.
Plasmid constructs. The -290/+157 Smad3-LUC construct containing Smad3 promoter sequences was generated as followed. The Smad3 promoter sequences from -1733/+157 or -1034/+157 obtained by PCR amplification using the "Advantage GC genomic polymerase mix" (Clontech laboratories) and human genomic DNA (Roche Applied Science) as a template were subcloned into the pGL3basic vector, which carries the luciferase reporter gene without a promoter (Promega). The resulting clones were used to generate the 5'deletion mutant -290/+157 Smad3-LUC by digestion with SmaI and religation with the T4 DNA ligase (Invitrogen). Two clones were verified by sequencing.
Statistical analysis. Statistical differences between experimental groups were determined by analysis of variance using StatView 4.02 software program for Macintosh. Values of P<0.05 by Fisher's PLSD were considered significant. Differences between two comparative groups were further analyzed by unpaired student t test.
RESULTS
Smad3 protein down-regulation. While studying activation of the Smad pathway in human glomerular mesangial cells, we observed that Smad3 protein levels were decreased in response to TGF-β1 (15) . However, we also have shown that Smad3 is required for TGF-β1-stimulated COL1A2 gene expression since overexpression of a Smad3 dominant-negative mutant or mutation of the Smad binding site in the COL1A2 promoter blocks its induction by TGF-β1 (15, 16) . Here we sought to study the mechanism by which TGF-β1 regulates Smad expression. Smad3, but not Smad2 or Smad4, is significantly decreased by 24 h of TGF-β1 treatment in mesangial cells ( Figure  1A ). In these cells, Smad3 levels remain low for up to 72 h of incubation with TGF-β1 (data not shown). It should be noted that Smad2 protein expression is increased after 6 h of treatment with TGF-β1 but returns to control levels at 24 h ( Figure 1A ). We next examined whether TGF-β1-induced Smad3 down-regulation is dependent on an active TGF-β receptor complex. Figure 1B shows that the TGF-β type I receptor (Alk5/TβRI) kinase inhibitor SB-431542 blocks TGF-β1-induced Smad3 phosphorylation and downregulation, suggesting that decreased Smad3 expression requires an active Alk5/TβRI.
Role of the ubiquitin-proteasome pathway. Since polyubiquitination is generally considered to be a marker of protein degradation by the proteasome pathway (27) , we examined the extent of Smad3 ubiquitination in response to TGF-β1. Figure 2 shows that endogenous Smad3 is polyubiquitinated after 24 h of TGF-β 1 stimulation in mesangial cells. Treatment with proteasome inhibitors prevents the decrease in Smad3 protein levels ( Figure 3 ) and leads to accumulation of polyubiquitinated Smad3 (data not shown). These data suggest that the TGF-β1-induced Smad3 down-regulation occurs via the ubiquitin-proteasome pathway.
Smad3 gene expression. Previously, we showed that, in addition to affecting Smad3 protein expression, TGF-β1 modulates Smad3 mRNA levels in mesangial cells, with Smad3 mRNA expression significantly decreased following 4 h of incubation with TGF-β1, while Smad2 and Smad4 mRNA levels remained unchanged (15) . To determine whether the effect of TGF-β1 on Smad3 down-regulation was direct or not, we examined whether cycloheximide affected Smad3 mRNA expression. Figure 4 A shows that cycloheximide alone increases Smad3 mRNA levels. However, it impairs TGF-β1 -induced inhibition, suggesting that de novo protein synthesis may be required for Smad3 mRNA down-regulation in response to TG-β1. Next, we investigated whether TGF-β1 affects Smad3 mRNA stability. An analysis of mRNA half-life using actinomycin D to inhibit transcription ( Figure 4B) shows that TGF-β1 does not increase the rate of turnover for Smad3 mRNA, suggesting that the TGF-β1-induced decline in Smad3 mRNA level is not due to decreased mRNA stability.
Regulation of Smad3 promoter activity. Our results in Figure 4B suggest that TGF-β1 inhibits mesangial cell Smad3 expression by a transcriptional mechanism. To evaluate this, we generated a Smad3 promoter luciferase reporter construct and assessed the effect of TGF-β1 on Smad3 promoter activity in transient transfection experiments. The Smad3-LUC construct shows increased activity of 137-fold over the empty vector ( Figure 5 ). Moreover, TGF-β1 treatment significantly inhibits Smad3 promoter activity whereas it has no effect on the control empty reporter construct pGL3basic. These data suggest that, in addition to decreasing Smad3 protein stability via the ubiquitin-proteasome pathway (Figure 2 ), TGF-β1 also inhibits Smad3 gene transcription.
Smad3 down-regulation in cells with a myofibroblastic phenotype. Next we sought to compare the effect of TGF-β 1 on Smad3 expression in various cell types to determine whether the TGF-β1-induced Smad3 downregulation is a general cell response. In contrast to what we observed in mesangial cells, treatment with TGF-β 1 for 24 h does not affect the expression of any of the three Smad proteins examined in renal tubular epithelial HKC cells, although the Smad pathway is activated by TGF-β 1 as determined by increased Smad3 phosphorylation ( Figure 6A ). Similarly, we do not observe any Smad3 decline within this time frame in other epithelial cells, including the mouse mammary gland epithelial cell line NMuMG and mink lung epithelial cell line Mv1Lu (data not shown). Increasing evidence suggests that renal myofibroblasts, whose activation is thought to play a critical role in the progression of renal fibrosis by contributing to ECM overproduction, may derive at least in part from tubular epithelial cells via EMT (1, 28, 29) . Since TGF-β has been shown to induce renal tubular cell EMT (30), we examined whether prolonged TGF-β1 treatment affects Smad3 expression following myofibroblastic phenotypic changes in HKC.
Time course experiments show a significant decrease in Smad3 levels after 7 days of exposure to TGF-β1 ( Figure 6B ). In contrast, Smad2 and Smad4 levels remain unchanged. The timing of the decline in Smad3 expression coincides with a change to a myofibroblastic phenotype, as demonstrated by increased expression of smooth muscle α-actin (α−SMA), a myofibroblast marker, and decreased expression of E-cadherin, an epithelial cell marker ( Figure 6B) ; and enhanced collagen I accumulation (data not shown).
Next, we examined whether Smad3 downregulation occurs in HKC via a mechanism similar to what we observed in human mesangial cells. Figure 7A shows that Smad3 is polyubiquitinated in HKC after 3 to 7 days of TGF-β1 treatment, suggesting that Smad3 protein is targeted for degradation by the proteasome pathway in these cells, albeit in delayed fashion consistent with the occurrence of EMT. In addition, incubation with TGF-β1 leads to a progressive decrease in Smad3 mRNA expression ( Figure 7B ). These results suggest that, similar to what we demonstrated in human mesangial cells, Smad3 down-regulation in HKC following long-term treatment with TGF-β1 involves both increased protein degradation and inhibition of transcription.
Unilateral ureteral obstruction (UUO) is a model of tubulointerstitial fibrosis associated with TGF-β up-regulation that causes EMT of renal tubules and ECM accumulation (23, 31, 32) . Thus, we examined Smad3 expression after UUO. Smad3 levels are progressively decreased in the affected kidney following UUO in mice ( Figure  8 ). The decline is concomitant with increased αSMA expression after 3 days, up to 14 days of obstruction.
These changes correlate with increased TGF-β and TβRI expression in renal tubular epithelium of the obstructed kidney (31) as well as increased TGF-β 1 mRNA (data not shown). Together, our findings suggest that Smad3 down-regulation is a cell type-specific event, occurring in response to TGF-β1 in cells with a fibroblastoid phenotype but not in epithelial cells.
DISCUSSION
Since Smad3 plays a critical role in wound healing and the pathogenesis of fibrosis, determining how Smad3 is regulated is essential to understanding the mechanisms of these processes. Here, we show that TGF-β1 down-regulates Smad3 levels in a cell phenotype-specific manner. This down-regulation is due to both increased degradation via the proteasome pathway and decreased gene transcription.
Only a few studies have examined Smad3 turnover (18) (19) (20) . Potential E3 ubiquitin ligases reported to target Smad3 for degradation are the RING finger ubiquitin ligase ROC1 and the carboxy terminus of Hsc70 interacting protein (CHIP). The role of ROC1 is still controversial. Fukuchi and colleagues have suggested that overexpressed ROC1 interacts with activated Smad3 and triggers its degradation in COS7 cells (18) , whereas Inoue et al. were unable to detect interaction between Smad3 and ROC1 in HEK293T cells even after TGF-β stimulation (19) . Overexpression of CHIP in several cell lines decreases basal Smad3 levels but independently of TGF-β signaling (20) . It is important to note that, in these studies, overexpressed Smad3 and ubiquitin were used and required overexpression of the E3 ligase complex ROC1-SCF Fbw1a or CHIP and/or the presence of proteasome inhibitor to detect Smad3 ubiquitination. In contrast, we show a decline in endogenous Smad3 in mesangial cells within 24 h in response to TGF-β1, and that TGF-β 1 treatment increases ubiquitination of endogenous Smad3 targeting it for degradation by the proteasome machinery. Whether ROC1, CHIP or other E3 ligases play a role in endogenous Smad3 down-regulation remains to be examined. Interestingly, protein and mRNA expression of the closely related Smad2 are not affected by 24 h of treatment with TGF-β1 in human mesangial cells (present report and (15)). Since Smad2 and Smad3 have distinct roles that may also be cell type-specific (33) (34) (35) , differential regulation of Smad2 and Smad3 are likely to affect how cells respond to TGF-β.
T G F -β induces ECM accumulation in fibroblasts and mesenchymal cells such as glomerular mesangial cells, while it inhibits proliferation and/or induces apoptosis and EMT in several epithelial cells including renal tubular epithelial cells (2, (5) (6) (7) . The interactions of the Smad cascade with other signaling pathways contribute to the specificity of the response (36, 37) . Here, we have identified a cell response that is both phenotype-and Smad type-specific. This specific Smad3 down-regulation may play a role in modulating TGF-β signals.
In addition to decreasing Smad3 protein levels, our data show that TGF-β1 also modulates Smad3 mRNA expression. Although Smad3 mRNA down-regulation has been observed in two immortalized human lung epithelial cell lines, BEASB2B and HPL1A (38) , and in normal skin and lung fibroblasts (39, 40) , the mechanism by which this occurs has not been described. Here we show that the TGF-β1-induced decrease in Smad3 mRNA expression is not due to an alteration in mRNA stability, but rather to decreased promoter activity. In addition, our experiment with cycloheximide suggests that Smad3 downregulation by TGF-β1 requires de novo synthesis of proteins such as transcription factors and/or cytokines that might act as autocrine or paracrine mediators. Of note, cycloheximide alone increases expression of Smad3 mRNA. This may result from increased stability of mRNA due to inhibition of synthesis of proteins involved in RNA degradation or relief of transcriptional repression Although TGF-β -enhanced, ubiquitinmediated Smad3 degradation has been reported previously, the data suggested that Smad3 expression is compensated by concomitant increased Smad3 synthesis in the time frame examined (18) (19) (20) . Thus the result of this response appears to be that turnover is increased but protein levels are stable. Our data suggest that a critical additional event in mesenchymal cells, inhibition of promoter activity, plays an important role in decreasing Smad3 expression. This is the first report showing regulation of an R-Smad promoter activity by TGF-β1. Because the decline in Smad3 is phenotype-specific, we hypothesize that inhibition of Smad3 gene expression could be part of a feedback loop controlling TGF-β signaling. Increased expression of the inhibitor Smad7 has been associated with inhibition of TGF-β signaling (41) . Smad7 may regulate TGF-β signaling by inhibiting R-Smad activation by TβRI (41, 42) or by enhancing TβRI degradation (43, 44) . PIASy (protein inhibitor of activated STAT) and TLP (TRAP-1-like protein) may also negatively regulate TGF-β /Smad3-mediated signaling (45, 46) . Here, we suggest an additional mechanism for controlling TGF-β responses that involves a decrease in Smad3 expression by inhibition of gene transcription as well as increased protein degradation.
Our data show that, although tubular epithelial cell Smad3 levels are unaffected by 24 h of treatment with TGF-β1, prolonged exposure to TGF-β1 leads to a significant decline in Smad3 expression. These changes parallel decreased Ecadherin and increased α-SMA expression, suggesting that decreased Smad3 expression occurs with EMT. Similar results were obtained in kidney following UUO which is associated with EMT of the tubules. Since Smad3 has been shown to be essential for the initiation of EMT after UUO and in cultured tubular epithelial cells (32) , the decline in Smad3 levels following EMT suggest that Smad3 down-regulation could represent a feedback loop controlling TGF-β1 responses. Interestingly, in a model of lung fibrosis induced by bleomycin, Smad3 expression decreased during the reparative phase of lung injury at days 8 and 12 (40) . In addition, Kelley at al. found reduced Smad3 protein levels in a model of cystic fibrosis compared to those in control mice (47) . It is intriguing that rat and mouse UUO kidneys show increased nuclear localization of phosphoSmad2/3 in some glomerular and tubulointerstitial cells (48, 49) . Since we detected a decrease in total Smad3 expression in mouse UUO kidneys, this raises questions regarding whether the active or inactive form of Smad3 is targeted for degradation following UUO and whether and how the residual active Smad3 contributes to renal fibrosis.
In summary, we have shown that TGF-β1 down-regulates Smad3 in cells with a myofibroblatic phenotype. The down-regulation involves protein degradation via the ubiquitin/proteasome pathway and inhibition of gene transcription. Since Smad3 is a key mediator of fibrosis, understanding the causes and effects of changes in Smad3 expression may provide a model to suggest specific means to block fibrotic diseases. 
